Impact of scatter correction on D2 receptor occupancy measurements using 123I-IBZM SPECT: Comparison to 11C-Raclopride PET

NeuroImage

Volumn 50, Issue 4, 2010, Pages 1511-1518

  Bullich, S ^a   Cot, A ^b,c   Gallego, J ^b,d   Gunn, R N ^e,h   Suarez M ^a   Pavia J ^c,f,g   Ros, D ^b,c,g   Laruelle, M ^e,h   Catafau, A M ⁱ  

^a Barcelona Biomedical Research Park   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^d UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^e GLAXOSMITHKLINE   (United Kingdom)

^f HOSPITAL CLÍNIC   (Spain)

^g INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ GLAXOSMITHKLINE   (Spain)

Author keywords

11C Raclopride PET; 123I IBZM SPECT; Antipsychotic; D2 receptor occupancy; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; RACLOPRIDE C 11;

ADULT; ARTICLE; BRAIN REGION; CEREBELLUM CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUMAN; IMAGE ANALYSIS; INFORMATION PROCESSING; INTERMETHOD COMPARISON; MALE; NEUROIMAGING; OCCIPITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ALGORITHMS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BRAIN; BRAIN MAPPING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MODELS, NEUROLOGICAL; PHANTOMS, IMAGING; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SCATTERING, RADIATION; SIGNAL PROCESSING, COMPUTER-ASSISTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77950593138     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2010.01.013     Document Type: Article

References (42)

1. Beekman F.J., de Jong H.W.A.M., and van Geloven S. Efficient fully 3-D iterative SPECT reconstruction with Monte Carlo-based scatter compensation. IEEE. Trans. Med. Imag. 21 8 (2002) 867-877
2. Bullich S., Ros D., Pavía J., Cot A., López N., and Catafau A.M. Neurotransmission SPECT and MR registration combining mutual and gradient information. Med. Phys. 36 11 (2009) 4903-4910
3. Catafau A.M., Bullich S., Danús M., Penengo M.M., Cot A., Abanades S., et al. Test-retest variability and reliability of 123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms. Synapse 62 1 (2008) 62-69
4. Catafau A.M., Suarez M., Bullich S., Llop J., Nucci G., Gunn R., et al. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. NeuroImage 46 (2009) 447-458
5. Cot A., Sempau J., Pareto D., Bullich S., Pavía J., Calviño F., et al. Study of the point spread function (PSF) for 123I SPECT imaging using Monte Carlo simulation. Phys. Med. Biol. 9 14 (2004) 3125-3136
6. Cot A., Falcón C., Crespo C., Sempau J., Pareto D., Bullich S., et al. Absolute quantification in dopaminergic neurotransmission SPECT using a Monte Carlo-based scatter correction and fully 3-dimensional reconstruction. J. Nucl. Med. 46 9 (2005) 1497-1504
7. Cot A., Jane E., Sempau J., Falcon C., Bullich S., Pavia J., et al. Modeling of high-energy contamination in SPECT imaging using Monte Carlo simulation. IEEE. Trans. Nucl. Sci. 53 (2006) 198-203
8. Crespo C., Gallego J., Cot A., Falcón C., Bullich S., Pareto D., et al. Quantification of dopaminergic neurotransmission SPECT studies with (123)I-labelled radioligands. A comparison between different imaging systems and data acquisition protocols using Monte Carlo simulation. Eur. J. Nucl. Med. Mol. Imaging. 35 7 (2008) 1334-1342
9. Dobbeleir A.A., Hambÿe A.S., and Franken P.R. Influence of high-energy photons on the spectrum of iodine-123 with low-and medium-energy collimators: consequences for imaging with 123I-labelled compounds in clinical practice. Eur. J. Nucl. Med. 26 6 (1999) 655-658
10. Dresel S., Mager T., Rossmüller B., Meisenzahl E., Hahn K., Möller H.J., et al. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. Eur. J. Nucl. Med. 26 8 (1999) 862-868
11. Fujita M., Varrone A., Kim K.M., Watabe H., Zoghbi S.S., Seneca N., Tipre D., Seibyl J.P., Innis R.B., and Iida H. Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [123I]epidepride SPET. Eur. J. Nucl. Med. Mol. Imaging. 31 (2004) 644-654
12. Harrison R.L., Vannoy S.D., Haynor D.R., Gillispie S.B., Kaplan M.S., and Lewellen T.K. Preliminary experience with the photon history generator module of a public-domain simulation systems for emission tomography. Records of IEEE Nuclear Science Symposium and Medical Imaging Conference, San Francisco (1993) 1154-1158
13. Hietala J., Någren K., Lehikoinen P., Ruotsalainen U., and Syvälahti E. Measurement of striatal D2 dopamine receptor density and affinity with [11C]-raclopride in vivo: a test-retest analysis. J. Cereb. Blood. Flow. Metab. 19 2 (1999) 210-217
14. Hudson H.M., and Larkin R.S. Accelerated image reconstruction using ordered subsets of projection data. IEEE. Trans. Med. Imag. 13 4 (1994) 601-609
15. Ito H., Iida H., Kinoshita T., Hatazawa J., Okudera T., and Uemura K. Effects of scatter correction on regional distribution of cerebral blood flow using I-123-IMP and SPECT. Ann. Nucl. Med. 13 (1999) 331-336
16. Kegeles L.S., Zea-Ponce Y., Abi-Dargham A., Rodenhiser J., Wang T., Weiss R., et al. Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31 4 (1999) 302-308
17. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., Rodenhiser-Hill J., Mann J.J., Van Heertum R.L., et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry 48 7 (2000) 627-640
18. Kim K.M., Watabe H., Shidahara M., Ishida Y., and Iida H. SPECT collimator dependency of scatter and validation of transmission-dependent scatter compensation methodologies. IEEE Trans. Nucl. Sci. 48 3 (2001) 689-696
19. Kim K.M., Watabe H., Shidahara M., Onishi Y., Yonekura Y., and Iida H. Impact of scatter correction in the kinetic analysis of a D2 receptor ligand SPECT study. IEEE Medical Imaging Conference, San Diego (2001) 1509-1512
20. Knable M.B., Heinz A., Raedler T., and Weinberger D.R. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res. 75 2 (1997) 91-101
21. Koch W., Hamann C., Welsch J., Pöpperl G., Radau P.E., and Tatsch K. Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies?. J. Nucl. Med. 46 11 (2005) 1804-1811
22. Koch W., Radau P.E., Münzing W., and Tatsch K. Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom. Eur. J. Nucl. Med. Mol. Imaging 33 4 (2006) 495-502
23. Lammertsma A.A., and Hume S.P. Simplified reference tissue model for PET receptor studies. NeuroImage 4 (1996) 153-158
24. Larsson A., Ljungberg M., Jakobson Mo S., Riklund K., and Johansson L. Correction for scatter and septal penetration using convolution subtraction methods and model-based compensation in 123I brain SPECT imaging-a Monte Carlo study. Phys. Med. Biol. 51 (2006) 5753-5767
25. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood. Flow. Metab. 20 3 (2000) 423-451
26. Laruelle M. The role of model-based methods in the development of single scan techniques. Nucl. Med. Biol. 27 7 (2000) 637-642
27. Laruelle M., Slifstein M., and Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 27 3 (2002) 287-299
28. Moore S.C., Kijewski M.F., Muller S.P., Rybicki F., and Zimmerman R.E. Evaluation of scatter compensation methods by their effects on parameter estimation from SPECT projections. Med. Phys. 28 (2001) 278-287
29. Pareto D., Cot A., Pavía J., Falcón C., Juvells I., Lomeña F., et al. Iterative reconstruction with correction of the spatially variant fan-beam collimator response in neurotransmission SPET imaging. Eur. J. Nucl. Med. Mol. Imaging 30 10 (2003) 1322-1329
30. Shiga T., Kubo N., Takano A., Kobayashi J., Takeda Y., Nakamura F., et al. The effect of scatter correction on 123I-IMP brain perfusion SPET with the triple energy window method in normal subjects using SPM analysis. Eur. J. Nucl. Med. 29 (2002) 342-345
31. 123I imaging. Phys. Med. Biol. 51 (2006) N307-N311
32. Soret M., Koulibaly P.M., Darcourt J., Hapdey S., and Buvat I. Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. J. Nucl. Med. 44 7 (2003) 1184-1193
33. Soret M., Koulibaly P.M., Darcourt J., and Buvat I. Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification. Eur. J. Nucl. Med. Mol. Imaging 33 9 (2006) 1062-1072
34. Staelens S., de Wit T., and Beekman F. Fast hybrid SPECT simulation including efficient septal penetration modelling (SP-PSF). Phys. Med. Biol. 52 11 (2007) 3027-3043
35. Talbot P.S., and Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur. Neuropsychopharmacol. 12 6 (2002) 503-511
36. 123I imaging. Phys. Med. Biol. 52 (2007) 4409-4425
37. Tauscher J., Küfferle B., Asenbaum S., Fischer P., Pezawas L., Barnas C., et al. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 141 2 (1999) 175-181
38. Varrone A., Sansone V., Pellecchia M.T., Amboni M., Salvatore E., De Michele G., et al. Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [(123)I]FP-CIT. Eur. J. Nucl. Med. Mol. Imaging. 35 7 (2008) 1343-1349
39. Verhoeff N.P., Brücke T., Podreka I., Bobeldijk M., Angelberger P., and Van Royen E.A. Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with 123I-IBZM using the rotating gamma camera. Nucl. Med. Commun. 12 8 (1991) 687-697
40. Volkow N.D., Fowler J.S., Wang G.J., Dewey S.L., Schlyer D., MacGregor R., et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J. Nucl. Med. 34 4 (1993) 609-613
41. Zaidi H., and Koral K.F. Scatter modelling and compensation in emission tomography. Eur. J. Nucl. Med. Mol. Imaging 31 5 (2004) 761-782
42. Zaidi H., and Montandon M.L. Which attenuation coefficient to use in combined attenuation and scatter corrections for quantitative brain SPECT?. Eur. J. Nucl. Med. 29 (2002) 967-969